Q3-osavuosiraportti

Vain PDF

13 päivää sitten

Tarjoustasot

Spotlight Stock Market DK

Määrä

Osto

186

Myynti

Määrä

419

Viimeisimmät kaupat

Aika	Määrä	Ostaja	Myyjä
14.31.00	128	NON	DDB
14.31.00	172	NON	DDB
13.25.28	400	DDB	NON
13.22.19	55	AVA	NON
12.47.02	19	NON	NON

Ylin

12,76

VWAP

12,43

Alin

11,8

VaihtoMäärä

0 4 008

VWAP

12,43

Ylin

12,76

Alin

11,8

VaihtoMäärä

0 4 008

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Ostaneet eniten

Ostaneet eniten
Välittäjä	Ostettu	Myyty	Netto	Sisäinen
Danske Bank A/S	900	300	+600	0
Avanza Bank AB	866	576	+290	11
Carnegie Investment Bank AB	133	0	+133	0
Nordnet Bank AB	2 109	2 432	−323	786
Svenska Handelsbanken AB	0	700	−700	0

Myyneet eniten

Myyneet eniten
Välittäjä	Ostettu	Myyty	Netto	Sisäinen
Svenska Handelsbanken AB	0	700	−700	0
Nordnet Bank AB	2 109	2 432	−323	786
Carnegie Investment Bank AB	133	0	+133	0
Avanza Bank AB	866	576	+290	11
Danske Bank A/S	900	300	+600	0

Yhtiötapahtumat

Seuraava tapahtuma
2025 Q4-osavuosiraportti	27.2.2026

Menneet tapahtumat
2025 Q3-osavuosiraportti	13.11.
2025 Q2-osavuosiraportti	21.8.
2025 Q1-osavuosiraportti	15.5.
2024 Yhtiökokous	28.3.
2024 Q4-osavuosiraportti	28.2.

Datan lähde: Millistream, Quartr

Asiakkaat katsoivat myös

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.

Kirjaudu

James doggo
17.11.
James doggo
17.11.
https://www.linkedin.com/posts/cessatech_we-are-very-pleased-to-welcome-sarah-margaux-activity-7396175071834308608-pXQv?utm_medium=ios_app&rcm=ACoAACinfHIBnoyHnRsRNFMQTM2ZWcZzUyAHUfY&utm_source=social_share_send&utm_campaign=copy_link
krsochr
17.11.
·
krsochr
17.11.
·
Difficult to figure out how competent the person is, but that's how it is at these levels, but a really good signal and a sign that commercialization is near!
Eftertanke
13.11.
·
Eftertanke
13.11.
·
It's quite absurd that it stays where it stays - production is underway, their CMO StaQ Pharma is owned, among others, by a number of children's hospitals - i.e., by Cessatech's primary customers. They must be able to sell almost everywhere to all hospitals in the USA, we are only waiting for the trucks to leave the factory - that is of course crucial, and sales figures are what will show it, but really - it's as if there are zero expectations for anything here, even though all signs point to something big, with approx. 0 risk. Is it because it's biotech, so people have burned their fingers too many times, or? I would say the share price should rise now, and then again (a lot), with good sales figures, next year.
LaurentiusO
13.11.
·
LaurentiusO
13.11.
·
Agreed. Normally, the price will reflect the potential revenues compared to the probability of them being realized. The probability of them coming to market is high for a drug (> 50% if one is very cautious). After this, one can speculate whether sales will end up at 200 - 400 mill USD as Ventil has suggested or less. Next, add revenue from the EU once the product is approved there. In addition to the value of the other development projects in their portfolio. But if Cessatech and their partners succeed reasonably well in fulfilling the potential for CT 001, the price could, by quick mental arithmetic, end up at 200 - 300 kr when sales take off. If one sets the probability of them reaching that point at 50%, a future price target of 100 - 150 kr is not unrealistic. And that stock can currently be bought for 11 - 12 kr (with a few months until expected launch). Or put another way, the confidence that Cessatech will achieve sales roughly in line with Ventis’ prediction is estimated, based on the current stock price, at 4 - 6%. It must undeniably be said to be somewhat on the conservative side.
LaurentiusO
18.11.
·
LaurentiusO
18.11.
·
Thanks for the information regarding the USA potential. The narrative only gets better because of it. In the EU, CT-01 must first be approved by the EU. It typically takes 12-15 months depending on questions/answers in the procedure. Since they submitted in September, they will probably get an approval in Q4 and can launch in the first countries by the end of 2026. However, for some countries, negotiations and subsidy rules must be initiated, so I don't expect much sales before 2027. I also think that it will primarily be the USA that drives the business case.
lesgotoluchenbachtexas
12.11.
·
lesgotoluchenbachtexas
12.11.
·
5800 shares traded the day before the financial report. It seems like everything that needs to be priced in has been priced in. Yes, but it will be exciting tomorrow.
AktieHunter
5.11.
·
AktieHunter
5.11.
·
Why are we going down again...
asromadk
5.11. · Muokattu
·
asromadk
5.11. · Muokattu
·
It is expected, I would say. Really good that CMO was appointed, but this is one of those with the bear and the skin. 1/2 has been announced, a really important step. Now 2/2 is waiting, and here it is currently priced into the market that it might take some time... That being said, it will be really exciting when they then call for full sails on it in the spring - and from there, real numbers must also be delivered, and Cessa will be a company where the financial statements will increasingly be scrutinized. Also not an easy game. So all this about believing that it could rise much more than 10-20% on news like the CMO being in place is probably naive. It is finding a new level now and it will be interesting to see if it shows the same strength at the bottom as it did with 10 all these months. I wonder if it will reject the idea of going below 11.5 or so. There will probably be support and buyers for it there, I think? And then otherwise lie and fluctuate between 11.5 and 12.5 as the wind blows on low vol. for the next many months.
Ja da
3.11.
Ja da
3.11.
Tämä julkaisu on poistettu.
Aim4it
3.11.
·
Aim4it
3.11.
·
Ah ok, so nothing new then.

Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset ja analyysit

Kaikki uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

Q3-osavuosiraportti

Vain PDF

13 päivää sitten

Uutiset ja analyysit

Kaikki uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.

Kirjaudu

James doggo
17.11.
James doggo
17.11.
https://www.linkedin.com/posts/cessatech_we-are-very-pleased-to-welcome-sarah-margaux-activity-7396175071834308608-pXQv?utm_medium=ios_app&rcm=ACoAACinfHIBnoyHnRsRNFMQTM2ZWcZzUyAHUfY&utm_source=social_share_send&utm_campaign=copy_link
krsochr
17.11.
·
krsochr
17.11.
·
Difficult to figure out how competent the person is, but that's how it is at these levels, but a really good signal and a sign that commercialization is near!
Eftertanke
13.11.
·
Eftertanke
13.11.
·
It's quite absurd that it stays where it stays - production is underway, their CMO StaQ Pharma is owned, among others, by a number of children's hospitals - i.e., by Cessatech's primary customers. They must be able to sell almost everywhere to all hospitals in the USA, we are only waiting for the trucks to leave the factory - that is of course crucial, and sales figures are what will show it, but really - it's as if there are zero expectations for anything here, even though all signs point to something big, with approx. 0 risk. Is it because it's biotech, so people have burned their fingers too many times, or? I would say the share price should rise now, and then again (a lot), with good sales figures, next year.
LaurentiusO
13.11.
·
LaurentiusO
13.11.
·
Agreed. Normally, the price will reflect the potential revenues compared to the probability of them being realized. The probability of them coming to market is high for a drug (> 50% if one is very cautious). After this, one can speculate whether sales will end up at 200 - 400 mill USD as Ventil has suggested or less. Next, add revenue from the EU once the product is approved there. In addition to the value of the other development projects in their portfolio. But if Cessatech and their partners succeed reasonably well in fulfilling the potential for CT 001, the price could, by quick mental arithmetic, end up at 200 - 300 kr when sales take off. If one sets the probability of them reaching that point at 50%, a future price target of 100 - 150 kr is not unrealistic. And that stock can currently be bought for 11 - 12 kr (with a few months until expected launch). Or put another way, the confidence that Cessatech will achieve sales roughly in line with Ventis’ prediction is estimated, based on the current stock price, at 4 - 6%. It must undeniably be said to be somewhat on the conservative side.
LaurentiusO
18.11.
·
LaurentiusO
18.11.
·
Thanks for the information regarding the USA potential. The narrative only gets better because of it. In the EU, CT-01 must first be approved by the EU. It typically takes 12-15 months depending on questions/answers in the procedure. Since they submitted in September, they will probably get an approval in Q4 and can launch in the first countries by the end of 2026. However, for some countries, negotiations and subsidy rules must be initiated, so I don't expect much sales before 2027. I also think that it will primarily be the USA that drives the business case.
lesgotoluchenbachtexas
12.11.
·
lesgotoluchenbachtexas
12.11.
·
5800 shares traded the day before the financial report. It seems like everything that needs to be priced in has been priced in. Yes, but it will be exciting tomorrow.
AktieHunter
5.11.
·
AktieHunter
5.11.
·
Why are we going down again...
asromadk
5.11. · Muokattu
·
asromadk
5.11. · Muokattu
·
It is expected, I would say. Really good that CMO was appointed, but this is one of those with the bear and the skin. 1/2 has been announced, a really important step. Now 2/2 is waiting, and here it is currently priced into the market that it might take some time... That being said, it will be really exciting when they then call for full sails on it in the spring - and from there, real numbers must also be delivered, and Cessa will be a company where the financial statements will increasingly be scrutinized. Also not an easy game. So all this about believing that it could rise much more than 10-20% on news like the CMO being in place is probably naive. It is finding a new level now and it will be interesting to see if it shows the same strength at the bottom as it did with 10 all these months. I wonder if it will reject the idea of going below 11.5 or so. There will probably be support and buyers for it there, I think? And then otherwise lie and fluctuate between 11.5 and 12.5 as the wind blows on low vol. for the next many months.
Ja da
3.11.
Ja da
3.11.
Tämä julkaisu on poistettu.
Aim4it
3.11.
·
Aim4it
3.11.
·
Ah ok, so nothing new then.

Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Spotlight Stock Market DK

Määrä

Osto

186

Myynti

Määrä

419

Viimeisimmät kaupat

Aika	Määrä	Ostaja	Myyjä
14.31.00	128	NON	DDB
14.31.00	172	NON	DDB
13.25.28	400	DDB	NON
13.22.19	55	AVA	NON
12.47.02	19	NON	NON

Ylin

12,76

VWAP

12,43

Alin

11,8

VaihtoMäärä

0 4 008

VWAP

12,43

Ylin

12,76

Alin

11,8

VaihtoMäärä

0 4 008

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Ostaneet eniten

Ostaneet eniten
Välittäjä	Ostettu	Myyty	Netto	Sisäinen
Danske Bank A/S	900	300	+600	0
Avanza Bank AB	866	576	+290	11
Carnegie Investment Bank AB	133	0	+133	0
Nordnet Bank AB	2 109	2 432	−323	786
Svenska Handelsbanken AB	0	700	−700	0

Myyneet eniten

Myyneet eniten
Välittäjä	Ostettu	Myyty	Netto	Sisäinen
Svenska Handelsbanken AB	0	700	−700	0
Nordnet Bank AB	2 109	2 432	−323	786
Carnegie Investment Bank AB	133	0	+133	0
Avanza Bank AB	866	576	+290	11
Danske Bank A/S	900	300	+600	0

Asiakkaat katsoivat myös

Yhtiötapahtumat

Seuraava tapahtuma
2025 Q4-osavuosiraportti	27.2.2026

Menneet tapahtumat
2025 Q3-osavuosiraportti	13.11.
2025 Q2-osavuosiraportti	21.8.
2025 Q1-osavuosiraportti	15.5.
2024 Yhtiökokous	28.3.
2024 Q4-osavuosiraportti	28.2.

Datan lähde: Millistream, Quartr

Tuotteita joiden kohde-etuutena tämä arvopaperi

Q3-osavuosiraportti

Vain PDF

13 päivää sitten

Uutiset ja analyysit

Kaikki uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Seuraava tapahtuma
2025 Q4-osavuosiraportti	27.2.2026

Menneet tapahtumat
2025 Q3-osavuosiraportti	13.11.
2025 Q2-osavuosiraportti	21.8.
2025 Q1-osavuosiraportti	15.5.
2024 Yhtiökokous	28.3.
2024 Q4-osavuosiraportti	28.2.

Datan lähde: Millistream, Quartr

Tuotteita joiden kohde-etuutena tämä arvopaperi

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.

Kirjaudu

James doggo
17.11.
James doggo
17.11.
https://www.linkedin.com/posts/cessatech_we-are-very-pleased-to-welcome-sarah-margaux-activity-7396175071834308608-pXQv?utm_medium=ios_app&rcm=ACoAACinfHIBnoyHnRsRNFMQTM2ZWcZzUyAHUfY&utm_source=social_share_send&utm_campaign=copy_link
krsochr
17.11.
·
krsochr
17.11.
·
Difficult to figure out how competent the person is, but that's how it is at these levels, but a really good signal and a sign that commercialization is near!
Eftertanke
13.11.
·
Eftertanke
13.11.
·
It's quite absurd that it stays where it stays - production is underway, their CMO StaQ Pharma is owned, among others, by a number of children's hospitals - i.e., by Cessatech's primary customers. They must be able to sell almost everywhere to all hospitals in the USA, we are only waiting for the trucks to leave the factory - that is of course crucial, and sales figures are what will show it, but really - it's as if there are zero expectations for anything here, even though all signs point to something big, with approx. 0 risk. Is it because it's biotech, so people have burned their fingers too many times, or? I would say the share price should rise now, and then again (a lot), with good sales figures, next year.
LaurentiusO
13.11.
·
LaurentiusO
13.11.
·
Agreed. Normally, the price will reflect the potential revenues compared to the probability of them being realized. The probability of them coming to market is high for a drug (> 50% if one is very cautious). After this, one can speculate whether sales will end up at 200 - 400 mill USD as Ventil has suggested or less. Next, add revenue from the EU once the product is approved there. In addition to the value of the other development projects in their portfolio. But if Cessatech and their partners succeed reasonably well in fulfilling the potential for CT 001, the price could, by quick mental arithmetic, end up at 200 - 300 kr when sales take off. If one sets the probability of them reaching that point at 50%, a future price target of 100 - 150 kr is not unrealistic. And that stock can currently be bought for 11 - 12 kr (with a few months until expected launch). Or put another way, the confidence that Cessatech will achieve sales roughly in line with Ventis’ prediction is estimated, based on the current stock price, at 4 - 6%. It must undeniably be said to be somewhat on the conservative side.
LaurentiusO
18.11.
·
LaurentiusO
18.11.
·
Thanks for the information regarding the USA potential. The narrative only gets better because of it. In the EU, CT-01 must first be approved by the EU. It typically takes 12-15 months depending on questions/answers in the procedure. Since they submitted in September, they will probably get an approval in Q4 and can launch in the first countries by the end of 2026. However, for some countries, negotiations and subsidy rules must be initiated, so I don't expect much sales before 2027. I also think that it will primarily be the USA that drives the business case.
lesgotoluchenbachtexas
12.11.
·
lesgotoluchenbachtexas
12.11.
·
5800 shares traded the day before the financial report. It seems like everything that needs to be priced in has been priced in. Yes, but it will be exciting tomorrow.
AktieHunter
5.11.
·
AktieHunter
5.11.
·
Why are we going down again...
asromadk
5.11. · Muokattu
·
asromadk
5.11. · Muokattu
·
It is expected, I would say. Really good that CMO was appointed, but this is one of those with the bear and the skin. 1/2 has been announced, a really important step. Now 2/2 is waiting, and here it is currently priced into the market that it might take some time... That being said, it will be really exciting when they then call for full sails on it in the spring - and from there, real numbers must also be delivered, and Cessa will be a company where the financial statements will increasingly be scrutinized. Also not an easy game. So all this about believing that it could rise much more than 10-20% on news like the CMO being in place is probably naive. It is finding a new level now and it will be interesting to see if it shows the same strength at the bottom as it did with 10 all these months. I wonder if it will reject the idea of going below 11.5 or so. There will probably be support and buyers for it there, I think? And then otherwise lie and fluctuate between 11.5 and 12.5 as the wind blows on low vol. for the next many months.
Ja da
3.11.
Ja da
3.11.
Tämä julkaisu on poistettu.
Aim4it
3.11.
·
Aim4it
3.11.
·
Ah ok, so nothing new then.

Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Spotlight Stock Market DK

Määrä

Osto

186

Myynti

Määrä

419

Viimeisimmät kaupat

Aika	Määrä	Ostaja	Myyjä
14.31.00	128	NON	DDB
14.31.00	172	NON	DDB
13.25.28	400	DDB	NON
13.22.19	55	AVA	NON
12.47.02	19	NON	NON

Ylin

12,76

VWAP

12,43

Alin

11,8

VaihtoMäärä

0 4 008

VWAP

12,43

Ylin

12,76

Alin

11,8

VaihtoMäärä

0 4 008

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Ostaneet eniten

Ostaneet eniten
Välittäjä	Ostettu	Myyty	Netto	Sisäinen
Danske Bank A/S	900	300	+600	0
Avanza Bank AB	866	576	+290	11
Carnegie Investment Bank AB	133	0	+133	0
Nordnet Bank AB	2 109	2 432	−323	786
Svenska Handelsbanken AB	0	700	−700	0

Myyneet eniten

Myyneet eniten
Välittäjä	Ostettu	Myyty	Netto	Sisäinen
Svenska Handelsbanken AB	0	700	−700	0
Nordnet Bank AB	2 109	2 432	−323	786
Carnegie Investment Bank AB	133	0	+133	0
Avanza Bank AB	866	576	+290	11
Danske Bank A/S	900	300	+600	0

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Ostaneet eniten

Myyneet eniten

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Ostaneet eniten

Myyneet eniten

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Ostaneet eniten

Myyneet eniten